BHIC 最新10-Q变化
将 BHIC 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-07 与上一份 10-Q · 2026-05-11
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +60 | −28 | ~6 | 8 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 0 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、风险因素、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-07
Our net loss for the three months ended June 30, 2026 was $185,753 compared to a net income of $457,704 during the three months ended June 30, 2025. The Company has generated revenue of $1,036,364 and $1,757,463 during the three months ended June 30, 2026 and 2025, respectively. This change is a res…
For the Quarter and Six Months Ended June 30, 2026 (Second Quarter 2026)
The following discussion should be read together with our unaudited financial statements and the related notes. This section contains forward-looking statements that reflect management's current expectations and are subject to risks and uncertainties. Statements regarding markets, valuation, product…
1. Executive Overview — Our Vision: "Ground Zero" Cellular Wellness
BioScience Health Innovations, Inc. ("BHIC," the "Company," "we") is the public-company platform for Best 365 Labs, a foundational-nutrition and cellular-health company. Our thesis is simple and, we believe, differentiated: almost every health journey begins — or should begin — at the cellular level…
相对上期删除的文字 · 来源:10-Q · 2026-05-11
THREE MONTHS ENDED MARCH 31, 2026 COMPARED TO MARCH 31, 2025
Currently, the Company is in the process of offering a private placement to accredited investors to raise up to $1,000,000. Once the private placement is complete the Company will begin the process of preparing and filing Form 1-A with the SEC.
BioScience Health Innovations Inc., through its wholly owned subsidiary Best 365 Labs, Inc., is a biotech and nutraceutical company focused on cellular health optimization, testosterone replacement therapy, and advanced nutrient delivery systems. The Company’s proprietary MODS Max (Mineral Oxide Del…
The Company operates from its headquarters in Bluffdale, Utah, manufactures non-prescription products through CGMP-compliant facilities, and maintains several 503A pharmacy relationships for the production of prescription-related products. BHIC is actively working toward establishing its own 503A co…
a)Flagship product: TPrime365 (MODS Max Gold) — a 4-in-1 sublingual testosterone optimizer containing Enclomiphene (25mg), Spermidine (10mg), Boron (10mg), and Vitamin C (10mg)
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议